News & Updates

Vaccination against COVID-19 seems to be less effective among kidney transplant recipients, according to a recent study. Cessation or reduction of immunosuppressive treatments may help increase the production of immunoglobulin (Ig)G in these patients.

The use of metformin, fluvoxamine, or ivermectin in an outpatient setting did not appear to prevent progression to severe COVID-19, according to results of the phase III COVID-OUT trial.  

Patients with complicated urinary tract infection (UTI) or acute pyelonephritis caused by gram-negative pathogens may fare better with cefepime/enmetazobactam than with piperacillin/tazobactam, as the former is associated with a greater likelihood of achieving treatment success, according to the results of a phase III trial.

Hepatitis B surface antigen (HBsAg) seroclearance appears to reduce the risk of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) late recurrence among patients who underwent curative liver resection, results of a Korea study have shown.

Patients with inflammatory rheumatic disease (IRD) have reduced levels of anxiety and self-isolation following the initial lockdown period brought about by the COVID-19 pandemic, reports a study.

Doxycycline, taken with 72 hours of unprotected sex, could prevent sexually transmitted infections (STIs) in men who have sex with men (MSM) or transgender women (TGW) who are either living with HIV (PLHIV) or are receiving pre-exposure prophylaxis (PrEP), according to a study presented at AIDS 2022.

Mothers who wish to breastfeed during periods of acute infections need strong support, especially during the COVID-19 pandemic, suggests a Singapore study.

Patients with psoriasis report improved quality of life under the COVID-19 pandemic despite harsh movement restrictions, a recent study has found. Such an effect, however, may suggest that current tools do not completely capture the negative impacts of harsh lockdowns on patients’ wellbeing.

Results of the STOP-COVID trial, presented at ERS 2022, showed no clinical outcome benefit with the dipeptidyl peptidase-1 (DPP-1) inhibitor brensocatib compared with placebo in patients hospitalized with COVID-19 in the UK.